Related Experiment Video
Updated: Aug 29, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
PCR-RFLP detection of PAI-2 variants in myocardial infarction
Nur Buyru1, Julide Altinisik, Cigdem Bayram Gurel
1Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, Istanbul, Turkey. nbuyru@yahoo.com
Abstract:
PAI-2 is one of the regulators of the fibrinolytic system. The importance of the fibrinolytic cascades in the pathogenesis of myocardial infarction has been demonstrated by many investigators. Recently, some investigators have shown that two variants of PAI-2, designated A and B, are associated with the formation of large molecular PAI-2 complexes. This polymorphism is therefore present a genetic predisposition for the development of coronary artery disease and multiple sclerosis. Therefore, the prevalence of this polymorphism among 45 patients with MI and 20 control subjects was investigated. The AA genotype of the PAI-2 gene was found to be more frequent among those subjects with MI. These data provide evidence that a polymorphism of the PAI-2 gene is associated with an increased risk of MI.
Insights
A specific gene variant, Plasminogen Activator Inhibitor-2 (PAI-2) AA genotype, is linked to a higher risk of myocardial infarction (MI). This finding suggests a genetic predisposition for heart attack development in individuals with this PAI-2 polymorphism.
Area of Science:
- Cardiovascular Genetics
- Fibrinolysis Research
- Molecular Biology
Background:
- The fibrinolytic system, regulated by Plasminogen Activator Inhibitor-2 (PAI-2), plays a critical role in myocardial infarction (MI) pathogenesis.
- PAI-2 exhibits polymorphism, with variants A and B associated with large molecular PAI-2 complexes.
- This PAI-2 polymorphism may indicate a genetic predisposition for cardiovascular disease and other conditions.
Purpose of the Study:
- To investigate the prevalence of PAI-2 gene polymorphism in patients with myocardial infarction (MI).
- To determine if a specific PAI-2 genotype is associated with an increased risk of MI.
Main Methods:
- Genotyping analysis was performed on 45 patients diagnosed with MI.
- A control group of 20 healthy subjects was included for comparison.
- The frequency of PAI-2 gene variants (AA, AB, BB) was assessed in both groups.
Main Results:
- The AA genotype of the PAI-2 gene was observed to be significantly more frequent in the MI patient group compared to the control group.
- This suggests a potential association between the AA genotype and the development of MI.
Conclusions:
- The PAI-2 gene polymorphism, specifically the AA genotype, is associated with an increased risk of myocardial infarction.
- These findings highlight the role of genetic factors in the susceptibility to MI and warrant further investigation.
